The PACIFICA trial is a randomized study in several categories of myelofibrosis, an uncommon type of cancer that affects the body’s blood and bone health. The purpose of this site is to educate health care professionals about the ongoing research in this area and opportunities for patient enrollment.
To learn more, visit:ClinicalTrials.gov
Study is being conducted in following countries. For a full list of PACIFICA clinical sites and site enrollment status, visit ClinicalTrials.gov.
*Pacritinib (commercially known as VONJO™) was approved by U.S. Food and Drug Administration (FDA) on February 28, 2022 for the treatment of adults with myelofibrosis with a platelet count below 50 x 109/L.
As the approved indication is identical to the patients enrolling on PACIFICA, enrollment of additional patients in the U.S. is closed effective March 2022.